

Enterprise One Pain Management Service

Executive Summary – 1 January to 31 December 2023



Patient profile

Enterprise One received 264 completed referral questionnaires in this period (all services, n = 21435)

Demographic information	Your service	All services
Sex (female)	57.6%	59.1%
Average age (years)	45.8	50.9
Interpreter required	1.2%	3.1%
Communication assistance required	3.1%	7.9%
Living in highest disadvantage area	15.9%	21.4%
Aboriginal and/or Torres Strait Islander	5.4%	5.8%

Clinical characteristics	Your service	All services
Average number of pain sites	4.0	4.3
Average number of comorbidities	1.8	2.6
% using opioids > 2 days/week	25.3	40.0
Average oMEDD (mg)	31.4	44.3
Average number of drug groups used	1.8	2.0
% outside normal BMI range	73.9	74.8
% experiencing pain >5 years	19.5	42.9
% unemployed due to pain	37.7	37.1

Services provided

	Your service	All services
Episodes of care started	288	17436
Waiting time* (median days)	51.5	54
Patients participating in education/orientation programs	23	4756
Patients assessed by multidisciplinary team	0	2094
No. of treatment pathways started	245	12110
Treatment pathway type (%)		
- Group program	49.8	25.2
- Individual	40.0	51.6
- Concurrent	10.2	16.0
- Other	0.0	7.3
Episodes of care ended	146	11179

* Days from referral received to episode start

Pain severity	5.6 ■	6.2 ■
Pain interference	6.5 ■	6.9 ■
	Mild / Moderate / Severe	
Depression	17.5 ■	18.8 ■
Anxiety	11.0 ■	12.9 ■
Stress	18.7 ■	19.8 ■
	Normal / Mild / Moderate / Severe / Extremely severe	
Pain catastrophising	24.4 ■	28.2 ■
	Mild / High / Severe	
Pain self-efficacy	22.2 ■	21.0 ■
	Minimal / Mild / Moderate / Severe impairment	

Collection of patient outcomes

A detailed summary of outcome collection rates at episode end and at post-episode follow-up can be found in the appendices of your report.

Benchmark & indicator summary

Benchmarks (BM)	BM target	Your service			All services		
		Patient outcomes included (n)	Positive outcomes* (%)	BM met?	Patient outcomes included (n)	Positive outcomes* (%)	Services met BM
Average pain <i>Patients with moderate or severe average pain at referral who have made a clinically significant improvement at episode end</i>	40%	83	30.1%	No	2876	28.9%	8/61
Pain interference <i>Patients with moderate or severe pain interference at referral who have made a clinically significant improvement at episode end</i>	70%	91	58.2%	No	3195	59.7%	14/63
Depression <i>Patients with moderate, severe or extremely severe depression at referral who have made a clinically significant improvement at episode end</i>	70%	61	50.8%	No	2168	55.5%	11/55
Anxiety <i>Patients with moderate, severe or extremely severe anxiety at referral who have made a clinically significant improvement at episode end</i>	50%	53	37.7%	No	1915	43.0%	13/51
Stress <i>Patients with moderate, severe or extremely severe stress at referral who have made a clinically significant improvement at episode end</i>	60%	47	44.7%	No	1726	60.2%	30/47
Pain catastrophising <i>Patients with high or severe pain catastrophising at referral who have made a clinically significant improvement at episode end</i>	70%	66	69.7%	No	2437	57.4%	11/54
Pain self-efficacy <i>Patients with impaired self-efficacy (moderate or severe) at referral who have made a clinically significant improvement at episode end</i>	60%	79	53.2%	No	2728	48.2%	16/58
Opioid use <i>Patients taking opioids at referral who report a reduction in their oMEDD[†] of at least 50% at episode end</i>	60%^{††}	34	38.2%	No	1295	53.3%	13/40
Opioid use (high dose) <i>Patients reporting 40mg or more oMEDD[†] at referral who report a reduction of at least 50% at episode end</i>	60%	6	-	-	432	47.5%	3/11
Indicators							
Wait time – 3 months <i>Episodes starting within 3 months of the referral being received</i>	-	286	86.0%	-	17266	65.8%	-
Wait time – 8 weeks <i>Episodes starting within 8 weeks of the referral being received</i>	-	286	58.0%	-	17266	51.4%	-

* Positive outcomes describes the percentage of patients making a clinically significant improvement, or reducing oMEDD by 50% or having their episode start within 3 months/8 weeks where relevant

† oMEDD = oral morphine equivalent daily dose

†† The all-dose opioid use benchmark has been raised from 50% to 60% from the 2022 mid-year report onwards

- is shown for the benchmarks and indicators where less than 10 outcomes are included